RxDoctor Payments Data

Jeffrey Cummings

Orthopaedic Surgery · Carson City, NVNPI 1740271238

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (47.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 39.7% of the total. Reporting peaked in 2021 at $10,137 and has fallen 63.6% since, to $3,686 in 2025.

$25,187in general payments, 2019–2025

Across 51 payments — averaging $493.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$10K
  • Acadia Pharmaceuticals Inc$6K
  • Eisai Inc.$5K
  • Sanofi US Services Inc.$2K
  • H. Lundbeck A S$835
  • Stryker$462
  • plus $708 from 13 others
$23,204in research payments, 2019–2025

Across 7 payments — averaging $3314.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$20K
  • F. Hoffmann-la Roche AG$3K

What the payments were for

  • Consulting fees$10,99344%
  • Speaking & faculty fees$12,00048%
  • Travel & lodging$1,1535%
  • Food & beverage$1,0404%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,187 in reported general payments places this provider in the 80th percentile of 135 orthopaedic surgery providers in Nevada.

See all orthopaedic surgery providers in Nevada

Medicare billing

Part B allowed, 2024
$208,199
Medicare patients
395
Services billed
2,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$119
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$57
Meloxicam14$27

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in Carson City

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →